Skip to main content
. 2012 May 31;7(5):e38438. doi: 10.1371/journal.pone.0038438

Figure 5. Treatment of DIO mice with either FGF19 or FGF21 improves metabolic dysfunction.

Figure 5

Administration of recombinant FGF19 or FGF21 led to a reduction in body mass in a dose dependent fashion (A). Both FGF19 and FGF21 therapy led to a trend towards increased food intake, however, these differences were not significant (B). Treatment with FGF19 or FGF21 significantly reduced adiposity at both doses tested again in a dose dependant manner (C), All FGF treatments caused a significant reduction in serum glucose in DIO animals, furthermore, the reduction in glucose observed with the two proteins was strikingly similar (D).